Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 7 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 2 |
| Generics in Cardiovascular Diseases Market to 2018 Introduction | 12 | 1 |
| Generics in Cardiovascular Diseases Market to 2018 - Global Market Overview | 13 | 8 |
| Introduction | 13 | 1 |
| Antidyslipidemics | 13 | 2 |
| Anti-Hypertensives | 15 | 1 |
| Generics in Various Classes | 15 | 1 |
| Rise in Generics in CVD Market | 15 | 1 |
| Factors Responsible for Increasing Costs Associated with Generics and Soon-to-be Generics | 15 | 1 |
| Revenue | 16 | 2 |
| Annual Cost of Therapy | 18 | 1 |
| Treatment Usage Patterns | 19 | 1 |
| Disease population | 20 | 1 |
| Treatment Seeking Population | 20 | 1 |
| Diagnosed Population | 20 | 1 |
| Prescription Population | 20 | 1 |
| Generics in Cardiovascular Disease Market to 2018 - Geographical Landscape | 21 | 13 |
| The US | 21 | 1 |
| Revenue | 21 | 1 |
| Annual Cost of Therapy | 22 | 2 |
| Treatment Usage Patterns | 24 | 1 |
| Disease population | 25 | 1 |
| Treatment Seeking Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 25 | 1 |
| Top Five Countries of Europe | 26 | 1 |
| Revenue | 26 | 1 |
| Annual Cost of Therapy | 27 | 1 |
| Treatment Usage Patterns | 28 | 1 |
| Disease population | 29 | 1 |
| Treatment Seeking Population | 29 | 1 |
| Diagnosed Population | 29 | 1 |
| Prescription Population | 29 | 1 |
| Japan | 30 | 1 |
| Revenue | 30 | 1 |
| Annual Cost of Therapy | 31 | 1 |
| Treatment Usage Patterns | 32 | 1 |
| Disease population | 33 | 1 |
| Treatment Seeking Population | 33 | 1 |
| Diagnosed Population | 33 | 1 |
| Prescription Population | 33 | 1 |
| Generics in Cardiovascular Diseases Market to 2018- Therapeutic Landscape | 34 | 43 |
| Thrombosis | 34 | 1 |
| Introduction | 34 | 1 |
| Revenue | 35 | 1 |
| Annual Cost of Therapy | 36 | 1 |
| Treatment Flow Algorithm | 37 | 1 |
| Treatment Usage Pattern | 38 | 1 |
| Disease population | 39 | 1 |
| Treatment Seeking Population | 39 | 1 |
| Diagnosed Population | 39 | 1 |
| Prescription Population | 39 | 1 |
| Drivers and Restraints | 40 | 1 |
| Drivers | 40 | 1 |
| Patent Expiries of Major Blockbuster Drugs | 40 | 1 |
| Restraints | 40 | 1 |
| Expected Launch of Promising Molecules | 40 | 1 |
| Pulmonary Arterial Hypertension | 41 | 1 |
| Introduction | 41 | 1 |
| Pulmonary Arterial Hypertension | 41 | 1 |
| Pulmonary Venous Hypertension | 41 | 1 |
| Pulmonary Hypertension Associated With Hypoxemia | 42 | 1 |
| Pulmonary Hypertension Due to Chronic Thrombotic and/or Embolic Disease | 42 | 1 |
| Miscellaneous | 42 | 1 |
| Diagnosis of PAH is Primarily Carried out in the Following Ways: | 42 | 1 |
| Revenue | 43 | 1 |
| Annual Cost of Therapy | 44 | 2 |
| Treatment Usage Patterns | 46 | 1 |
| Disease population | 47 | 1 |
| Treatment-Seeking Population | 47 | 1 |
| Diagnosed Population | 47 | 1 |
| Prescription Population | 47 | 1 |
| Treatment Flow Algorithm | 48 | 1 |
| Drivers and Restraints | 48 | 1 |
| Drivers | 49 | 1 |
| Patent Expiry of Leading PAH Medication - Tracleer | 49 | 1 |
| Continued Uptake of Epoprostenol | 49 | 1 |
| Restraints | 49 | 1 |
| Low Treatment Seeking Behavior and Diagnosis in Pulmonary Arterial Hypertension | 49 | 1 |
| Expected To Launch of Novel Molecules Such As Macitentan and Riociguat | 49 | 1 |
| Hypertension | 50 | 1 |
| Introduction | 50 | 1 |
| Revenue | 51 | 1 |
| Annual Cost of Therapy | 52 | 1 |
| Treatment Flow Algorithm for Hypertension | 53 | 1 |
| Treatment Usage Patterns | 54 | 1 |
| Disease population | 55 | 1 |
| Treatment-Seeking Population | 55 | 1 |
| Diagnosed Population | 55 | 1 |
| Prescription Population | 55 | 1 |
| Drivers and Restraints | 56 | 1 |
| Drivers | 56 | 1 |
| Patent Expiries of Major Blockbusters | 56 | 1 |
| Rising Prevalence of Hypertension | 56 | 1 |
| Restraints | 56 | 1 |
| Increased Uptake of Combination Drugs | 56 | 1 |
| Dyslipidemia Market | 57 | 1 |
| Introduction | 57 | 1 |
| Revenue | 57 | 2 |
| Annual Cost of Therapy | 59 | 1 |
| Treatment Flow Algorithm | 60 | 1 |
| Treatment Usage Patterns | 61 | 1 |
| Disease population | 62 | 1 |
| Treatment Seeking Population | 62 | 1 |
| Diagnosed Population | 62 | 1 |
| Prescription Population | 62 | 1 |
| Drivers and Restraints | 62 | 1 |
| Drivers | 63 | 1 |
| Patent Expiry of Lipitor | 63 | 1 |
| Rising Prevalence of Dyslipidemia | 63 | 1 |
| Restraints | 63 | 1 |
| Expected Launch of Daralapib and Dalcetrapib | 63 | 1 |
| Coronary Artery Disease | 64 | 1 |
| Introduction | 64 | 1 |
| Revenue | 64 | 2 |
| Annual Cost of Therapy | 66 | 1 |
| Treatment Usage Patterns | 67 | 1 |
| Disease population | 68 | 1 |
| Treatment Seeking Population | 68 | 1 |
| Diagnosed Population | 68 | 1 |
| Prescription Population | 68 | 1 |
| Drivers and Restraints | 69 | 1 |
| Drivers | 69 | 1 |
| Rising Incidence of CAD | 69 | 1 |
| Increasing Prescription Rates | 69 | 1 |
| Drug Patent Expiries Leading to Increase in Generic Competition | 69 | 1 |
| Restraints Market | 70 | 1 |
| Promising Molecules in the Pipeline Dampen the Generics Market | 70 | 1 |
| Angina Pectoris Market | 70 | 1 |
| Introduction | 70 | 1 |
| Revenue | 71 | 1 |
| Cost of Therapy | 72 | 1 |
| Treatment Flow Algorithm | 73 | 1 |
| Treatment Usage Patterns | 74 | 1 |
| Disease population | 75 | 1 |
| Treatment Seeking Population | 75 | 1 |
| Diagnosed Population | 75 | 1 |
| Prescription Population | 75 | 1 |
| Drivers and Restraints | 75 | 1 |
| Drivers for the Angina Pectoris Market | 76 | 1 |
| Rise of Geriatric Population | 76 | 1 |
| Lifestyle Changes Increases Incidence of Angina | 76 | 1 |
| Patent Expiry of Major Blockbuster Drug Lipitor | 76 | 1 |
| Restraints for the Angina Pectoris Market | 76 | 1 |
| Adverse Effects Associated with Current Drugs Reduces Prescription | 76 | 1 |
| Generics in Cardiovascular Diseases Market to 2018 - Product Pipeline Analysis | 77 | 22 |
| Introduction | 77 | 1 |
| Research and Development Pipeline Pulmonary Arterial Hypertension | 78 | 3 |
| Research and Development Pipeline Dyslipidemia | 81 | 6 |
| Research and Development Pipeline Coronary Artery Disease | 87 | 2 |
| Research and Development Pipeline Angina Pectoris | 89 | 1 |
| Research and Development Pipeline Thrombosis | 89 | 3 |
| Research and Development Pipeline Hypertension | 92 | 7 |
| Generics in Cardiovascular Diseases Market to 2018 - Most Promising Pipeline Molecules | 99 | 3 |
| Eliquis | 99 | 1 |
| Introduction | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| RG1658 (Dalcetrapib, JTT-705, RO4607381) | 99 | 1 |
| Introduction | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| Clinical Trial Management 1 | 99 | 1 |
| MK-0524A (Cordaptive, niacin + laropiprant) | 100 | 1 |
| Introduction | 100 | 1 |
| Mechanism of Action | 100 | 1 |
| Clinical Trial Management 2 | 100 | 1 |
| AMR101 (LAX-101, Miraxion) | 101 | 1 |
| Introduction | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| Clinical Trial Management 3 | 101 | 1 |
| Generics in Cardiovascular Diseases Market to 2018 Competitive Landscape | 102 | 2 |
| Teva Pharma | 102 | 1 |
| Sandoz | 102 | 1 |
| Actavis | 102 | 1 |
| Apotex | 102 | 1 |
| Watson Pharmaceuticals | 103 | 1 |
| Watson Launches First Generic Lipitor (atorvastatin) | 103 | 1 |
| Mylan | 103 | 1 |
| Generics in Cardiovascular Diseases Market to 2018 Strategic Consolidations | 104 | 18 |
| Merger and Acquisition Deals (2004-2011) | 104 | 2 |
| Deals by Year | 106 | 1 |
| M&A Deals by Region | 107 | 1 |
| M&A Deals by Value | 108 | 1 |
| Deal Summary of Top 10 M&A Deals by Value | 109 | 1 |
| Takeda Pharmaceutical Acquires Nycomed International for $13.7 Billion - 2011 | 109 | 1 |
| Endo Pharmaceuticals Acquires Qualitest Pharmaceuticals - 2010 | 109 | 1 |
| Celgene Acquires Abraxis BioScience -2010 | 109 | 1 |
| Abbott Laboratories Acquires Solvay Pharmaceuticals for $7.6 Billion - 2009 | 109 | 1 |
| Gilead Sciences Acquires CV Therapeutics - 2009 | 110 | 1 |
| Daiichi Sankyo Acquires Majority Stake in Ranbaxy Laboratories - 2008 | 110 | 1 |
| Eli Lilly Acquires ICOS - 2006 | 110 | 1 |
| Sanofi-Synthelabo Merges with Aventis 2004 | 110 | 1 |
| Licensing Deals | 111 | 2 |
| Deals by Indication | 113 | 1 |
| Deals by Geography | 114 | 1 |
| Deals by Year | 115 | 1 |
| Deal Summary of Top Five Licensing Deals by Value | 116 | 1 |
| Amgen Enters Into a Licensing Agreement with Cytokinetics 2009 | 116 | 1 |
| United Therapeutics Enters Into Licensing Agreement with Eli Lilly 2008 | 116 | 1 |
| CV Therapeutics Enters Into Licensing Agreement with Menarini Group September 2008 | 116 | 1 |
| GlaxoSmithKline Enters Into Licensing Agreement with Myogen 2006 | 116 | 1 |
| Mylan Enters Into Licensing Agreement with Forest Laboratories 2006 | 116 | 1 |
| Co-development Deals | 117 | 1 |
| Deals by Indication | 117 | 1 |
| Deals by Geography | 118 | 1 |
| Deals by Year | 119 | 1 |
| Deal Summary of Top Five Co-development Deals by Value | 120 | 1 |
| Les Laboratoires Enters into Co-Development Agreement with miRagen Therapeutics | 120 | 1 |
| Boehringer Ingelheim Enters Into Agreement with Vitae Pharmaceuticals | 120 | 1 |
| Bristol-Myers Enters Into Co-Development Agreement with Pfizer | 120 | 1 |
| Cytokinetics Signs Strategic Agreement with Amgen | 120 | 1 |
| Metabolex Enters Into Co-Development Agreement with Ortho-Mcneil | 121 | 1 |
| Generics in Cardiovascular Diseases Market to 2018 - Appendix | 122 | 8 |
| Market Definitions | 122 | 1 |
| Abbreviations | 122 | 1 |
| Sources | 123 | 1 |
| Research Methodology | 124 | 6 |
| Coverage | 124 | 1 |
| Secondary Research | 125 | 1 |
| Primary Research | 125 | 1 |
| The report consists of the following four major sections | 125 | 1 |
| Therapeutic Landscape | 126 | 1 |
| Epidemiology-based Forecasting | 126 | 1 |
| Analogous Forecasting Methodology | 127 | 1 |
| Disease population | 127 | 1 |
| Treatment Seeking Population | 127 | 1 |
| Diagnosis Population | 127 | 1 |
| Prescription Population | 127 | 1 |
| Forecasting Model for Therapeutic Areas | 128 | 1 |
| Geographical Landscape | 129 | 1 |
| Pipeline Analysis | 129 | 1 |
| Competitive Landscape | 129 | 1 |
| Expert Panel Validation | 129 | 1 |
| Contact Us | 129 | 1 |
| Disclaimer | 129 | 1 |